



MEDI PURE

PHARMACEUTICALS

AN EXCITING 2019 EMERGING FOR MEDI PURE



A MESSAGE FROM THE CEO

2018 was an exciting year for Medipure, as much of what we consider to be the foundations for success were put into place from a planning, operations and staffing perspective. In 2019, we anticipate some very exciting developments that will advance our clinical research and move our business model to the next stage.

To advance both our commercial and strategic objectives, we are pleased to announce the appointment of Alan C. Mendelson of Latham & Watkins LLP as Corporate Secretary and Advisor to the Medipure Board of Directors. Mr. Mendelson represents emerging and public growth companies, primarily in the life-sciences industry. He will be of great assistance as Medipure takes the next step to advance our products into the pharmaceutical marketplace.

Expansions and additions to our Medipure research-family will also help us advance baseline molecular research and clinical trials for our full drug pipeline. Dr. Ognjen Brborović joins the Medipure Scientific Advisory Board, bringing with him a reputation as one of Croatia's most prominent professionals in pharmacoeconomics.

A notable addition as Medical Director to our Croatia base of operations is Dr. Miroslav Weiss. With a long history of clinical and health management experience in Zagreb, Dr. Weiss is a valuable addition offering practitioner and medical community insight to both our drug pipeline and clinical trials.

In the coming months, Medipure's two new wholly-owned subsidiaries in Zagreb, Croatia and Hyderabad, India will open their respective research centers. Expanding in this direction provides the Company with direct access to the European and Asian marketplace.

Medipure looks forward to the coming months, as we advance our agenda and move closer to our goal of leadership in endocannabinoid system-based prescription medications and advancing our drug pipeline to offer patients safe and effective alternatives.

- Boris Weiss, CEO

THE MEDIPURE TEAM IN ACTION

Left to Right: Boris Weiss, Dr. Nihar Pandey,
Mysia Gruber, Dr. Rakshit Kodekalra
Chaitra Appaiah, and Dave Pataky



RECENT APPOINTMENTS

MEDIPURE ANNOUNCES KEY ADDITION TO TAKE COMPANY TO NEXT STAGE OF DEVELOPMENT

Medipure Holdings Inc. announces the appointment of Alan C. Mendelson as Corporate Secretary and Advisor to the Board of Directors. Mr. Mendelson, of the firm Latham & Watkins LLP, represents emerging and public growth companies primarily in the life-sciences industry. He has managed and supervised a variety of major business transactions, including public offerings.

For more information, please click the link to visit [Medipure's website](#).

MEDIPURE ANNOUNCES KEY APPOINTMENT TO CROATIA SUBSIDIARY

Medipure Holdings Inc. announces the appointment of Dr. Miroslav Weiss as Medical Director of its subsidiary in Croatia. Dr. Weiss has a long history of clinical and health management experience in Zagreb, including a dual role as pediatrician and Director of Quality Control and Management at the Hospital for Children with Chronic Diseases. He currently practices in the Department of Pediatrics at University Clinical Hospital Centre.

For more information, please click the link to visit [Medipure's website](#).

MEDIPURE ANNOUNCES APPOINTMENT OF RENOWNED CROATIAN HEALTH SPECIALIST

Medipure Holdings Inc. announces the appointment of Dr. Ognjen Brborović to its Scientific Advisory Board. Dr. Brborović is one of Croatia's most prominent professionals in pharmaco-economics, having authored more than 20-scientific papers published in peer reviewed journals, in addition to completing more than 100-studies for some of the world's biggest pharmaceutical companies.

For more information, please click the link to visit [Medipure's website](#).

RECENT NEWS

The creation of two wholly-owned subsidiaries in India and Croatia are key aspects of Medipure's development. In the coming months, research centers in both locations will officially open. Medipure VP Corporate Development, Mysia Gruber, visited Croatia just weeks ago and recently took time to sit down and answer some questions about the company's move into the European Union.



Interview with Mysia Gruber, VP Corporate Development

1. What was the purpose of your recent trip to Croatia?

To meet our Croatian team, establish the operations for our Croatian subsidiary, and meet with our potential partners. We successfully identified a location with office space and lab facilities in Karlovac, located about 25 minutes south-west of Zagreb. This site will house full analytical labs for R&D along with a GMP facility to support our clinical trials.

2. Who did you meet with?

Our Croatian team which consists of Dr. Dubravko Kičić, Director of Operations, Dr. Miroslav Weiss, Medical Director, and Dr. Ognjen Brborović a member of our Scientific Advisory Board. We are very excited to have such expertise on our team. We had the opportunity to meet with Synthia Dodig, Trade Commissioner

for the Canadian Embassy in Zagreb and introduce Medipure and our research platform. We also met with Dr. Srećko Marušić from Dubrava Clinical Hospital (DCH), with whom we are establishing a partnership, to set up the first Phase-1 clinical trials site in Croatia, along with our CRO consultants Poliklinika Bonifarm and Altiora, LLC.

3. Expectations/goals for Croatia 2019?

We are very excited about the opportunities in Croatia, firstly establishing our lab facilities to expand our research and development along with an extensive clinical collaboration program with Dubrava Clinical Hospital. Secondly, there will be the potential to produce our drugs in compliance with European regulatory standards to support our clinical trials and eventual commercialization.

In North America we are faced with the opioid crisis; in Europe, the crisis involves medications for anxiety and mood disorders. Being a part of a company and team who are developing a new line of drugs to meet these needs and provide safe alternatives to patients is very rewarding. It makes it easy to get up each day knowing that you have the potential to help many patients and people worldwide!



KBD Klinička bolnica Dubrava
(Dubrava Clinical Hospital (DCH))

Left to Right: Dr. Marinko Bilušić, Director, Poliklinika Bonifarm; Dr. Nihar Pandey, CSO, Medipure; Mysia Gruber, VP Corporate Development, Medipure; Dr. Ognjen Brborović, Scientific Advisory Board, Medipure; Dr. Dubravko Kičić, Director of Operations, Medipure d.o.o.

VIDEOS TO WATCH

Medipure CEO Boris Weiss provides an early 2019 progress report and comments on a variety of significant developments anticipated to occur over the course of the year:





Croatia Expansion



India Expansion



Status of Patents

The material contained herein is provided solely for your general knowledge and is not intended to be a comprehensive review of all matters and developments concerning Medipure Holdings Inc. and Medipure Pharmaceuticals Inc. (collectively, "Medipure"). Medipure makes no representation or warranty regarding, and assumes no responsibility for, the use, validity, accuracy, completeness, reliability, or currency of any claims, statements, or information in this summary. This information does not constitute and should not be interpreted as an offer or the solicitation of an offer for the purchase of any securities of Medipure and is not intended in any way to qualify, modify, or supplement any information disclosed under the corporate and securities laws of any jurisdiction applicable to Medipure. No securities commission or similar authority in Canada or any other country or jurisdiction has in any way passed on any of the information contained in this summary.

FOR MORE INFORMATION

www.medipurepharmaceuticals.com or e-mail info@medipurepharma.com. Copyright © 2019 Medipure Pharmaceuticals Inc. All rights reserved. Want to change how you receive these emails? You can update your preferences or [unsubscribe from this list](#).

